Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.41 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.41 |
| ▸ | ITGAL | P20701 | 2/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.39 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.39 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | ITGAV | P06756 | 2/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9303848 | 0.83 | L3MBTL1 (0.54) | L3MBTL1ITGB2ICAM1ITGALITGB1 | |
| SCHEMBL25354603 | 0.81 | L3MBTL1 (0.46) | L3MBTL1ITGB2ICAM1ITGALITGB1 | |
| SCHEMBL25354606 | 0.81 | L3MBTL1 (0.46) | L3MBTL1ITGB2ICAM1ITGALITGB1 | |
| SCHEMBL38802 | 0.81 | OPRK1 (0.39) | — | |
| SCHEMBL29855148 | 0.81 | PPARG (0.48) | L3MBTL1ITGB2ICAM1ITGALPPARG | |
| SCHEMBL27977570 | 0.81 | PPARG (0.48) | L3MBTL1ITGB2ICAM1ITGALPPARG | |
| SCHEMBL16203412 | 0.81 | PPARG (0.48) | L3MBTL1ITGB2ICAM1ITGALPPARG | |
| SCHEMBL10065590 | 0.81 | PPARG (0.48) | L3MBTL1ITGB2ICAM1ITGALPPARG | |
| SCHEMBL6304792 | 0.81 | OPRK1 (0.39) | — | |
| SCHEMBL29522638 | 0.81 | ITGB2 (0.44) | L3MBTL1ITGB2ICAM1ITGALITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 426 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4397314-A1 | TREATMENT OF LEFT VENTRICULAR REMODELING | Stealth BioTherapeutics Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| US-11998585-B2 | Methods and compositions for increasing the dose of a chemotherapeutic agent | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240108740-A1 | THERAPEUTIC COMPOSITIONS INCLUDING SPN10 AND USES THEREOF | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-11944662-B2 | Methods and compositions for preventing or treating ophthalmic conditions | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-04-02 | — | — | US | disclosed |
| US-20240059735-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MITOCHONDRIAL MYOPATHIES | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-02-22 | — | — | US | disclosed |
| US-20240024408-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING LEBER'S HEREDITARY OPTIC NEUROPATHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-01-25 | — | — | US | disclosed |
| EP-4302829-A2 | PEPTIDE FOR USE IN PREVENTING OR TREATING MACULAR DEGENERATION | Stealth BioTherapeutics Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| US-11845807-B2 | Method and carrier complexes for delivering molecules to cells | CORNELL RESEARCH FOUNDATION, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20230398172-A1 | METHODS FOR PREVENTION AND TREATMENT OF ACUTE RENAL INJURY | CORNELL UNIVERSITY (US) | 2023-12-14 | — | — | US | disclosed |
| EP-4285994-A2 | METHODS FOR THE PREVENTION OR TREATMENT OF NO-REFLOW FOLLOWING ISCHEMIA/REPERFUSION INJURY | Stealth BioTherapeutics Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| US-20070015711-A1 | Administering aromatic cationic peptide for targeted mitochondria; antiischemic, -inflammatory, -arthritic, -diabetic agents, liver disorders, stroke; sepsis; viricides; organ removal; neurogenerative diseases; Parkingson's,Alzheimer's, Huntington's diseases; amyotrophic lateral sclerosis | CORNELL RESEARCH FOUNDATION, INC. | 2007-01-18 | — | — | US | disclosed |
| EP-1722807-A2 | METHODS FOR REDUCING OXIDATIVE DAMAGE | Cornell Research Foundation Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20060084606-A1 | administering aromatic cationic peptide for specifically target mitochondria; ischemia is due to stroke, sepsis, inflammatory process, arthritis, diabetes, liver disorders, viral infection, to a removed organ | CORNELL RESEARCH FOUNDATION, INC. | 2006-04-20 | — | — | US | disclosed |
| EP-1625149-A2 | METHOD AND CARRIER COMPLEXES FOR DELIVERING MOLECULES TO CELLS | CORNELL RESEARCH FOUNDATION, INC. (US) | 2006-02-15 | — | — | EP | disclosed |
| EP-1599216-A2 | METHODS FOR PREVENTING MITOCHONDRIAL PERMEABILITY TRANSITION | CORNELL RESEARCH FOUNDATION, INC. (US) | 2005-11-30 | — | — | EP | disclosed |
| WO-2005072295-A2 | METHODS FOR REDUCING OXIDATIVE DAMAGE | CORNELL RESEARCH FOUNDATION, INC. (US) | 2005-08-11 | — | — | WO | disclosed |
| US-20050158373-A1 | Small peptides that are energy-independent, non-endocytotic; nontoxic, peptidase resistant | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-07-21 | — | — | US | disclosed |
| WO-2005001023-A2 | METHOD AND CARRIER COMPLEXES FOR DELIVERING MOLECULES TO CELLS | CORNELL RESEARCH FOUNDATION, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| US-20040248808-A1 | Methods for preventing mitochondrial permeability transition | PUBLIC HEALTH SERVICE/NATIONAL INSTITUTES OF HEALTH (NIH) | 2004-12-09 | — | — | US | disclosed |
| WO-2004070054-A2 | METHODS FOR PREVENTING MITOCHONDRIAL PERMEABILITY TRANSITION | CORNELL RESEARCH FOUNDATION, INC. (US) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024408-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING LEBER'S HEREDITARY OPTIC NEUROPATHY | CLN6, PRPH, TSG101 | L3MBTL1 1588/4885ITGB2 4435/4885ICAM1 3502/4885 |
| US-11944662-B2 | Methods and compositions for preventing or treating ophthalmic conditions | CRYAA, CRYAB, IAPP | L3MBTL1 3155/4885ITGB2 1377/4885ICAM1 1032/4885 |
| US-20230398172-A1 | METHODS FOR PREVENTION AND TREATMENT OF ACUTE RENAL INJURY | ARG2, SERPINC1, ARG1 | L3MBTL1 916/4885ITGB2 1318/4885ICAM1 168/4885 |
| US-20240059735-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MITOCHONDRIAL MYOPATHIES | MTPN, CKMT1A; CKMT1B, TFAM | L3MBTL1 974/4885ITGB2 4732/4885ICAM1 4102/4885 |
| US-11998585-B2 | Methods and compositions for increasing the dose of a chemotherapeutic agent | OPRL1, TSG101, NGF | L3MBTL1 876/4885ITGB2 3996/4885ICAM1 1538/4885 |
| US-20240108740-A1 | THERAPEUTIC COMPOSITIONS INCLUDING SPN10 AND USES THEREOF | S100A10, SPG11, TMSB10 | L3MBTL1 1570/4885ITGB2 4842/4885ICAM1 4280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.